Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Non Operating Income: 2017-2025

Historic Non Operating Income for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to $5.4 million.

  • Cidara Therapeutics' Non Operating Income rose 190.21% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 135.65%. This contributed to the annual value of $5.8 million for FY2024, which is 191.28% up from last year.
  • Cidara Therapeutics' Non Operating Income amounted to $5.4 million in Q3 2025, which was up 223.83% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Cidara Therapeutics' Non Operating Income peaked at $5.4 million during Q3 2025, and registered a low of -$70,000 during Q1 2021.
  • Moreover, its 3-year median value for Non Operating Income was $1.7 million (2025), whereas its average is $1.5 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 418.18% in 2021, then skyrocketed by 10,483.33% in 2023.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Non Operating Income stood at -$33,000 in 2021, then surged by 590.91% to $162,000 in 2022, then spiked by 225.31% to $527,000 in 2023, then spiked by 244.02% to $1.8 million in 2024, then spiked by 190.21% to $5.4 million in 2025.
  • Its Non Operating Income stands at $5.4 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.8 million for Q1 2025.